<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114058</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00056482</org_study_id>
    <nct_id>NCT04114058</nct_id>
  </id_info>
  <brief_title>A Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine</brief_title>
  <official_title>Pain Outcomes Following Hip Arthroscopy: A Prospective Randomized Control Study Comparing Fascia Iliaca Blockade vs Extracapsular Local Field Infiltration With Liposomal Bupivacaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of fascia iliaca blockade vs local&#xD;
      field infiltration with liposomal bupivicaine in controlling pain, narcotic utilization and&#xD;
      falls in the postoperative period following hip arthroscopy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose the research is to help determine optimal means of post-operative analgesia&#xD;
      following hip arthroscopic procedures. Post-operative pain is a significant contributor to&#xD;
      patient satisfaction and the side effects of narcotic pain medication are well described. The&#xD;
      ideal intervention for achieving appropriate analgesia following hip arthroscopy has not yet&#xD;
      been defined. Determining means of achieving acceptable post-operative pain relief while&#xD;
      minimizing narcotic usage will help yield maximal patient outcomes.The primary research&#xD;
      procedures entailed in this study include fascia iliaca nerve blockade with Marcaine and&#xD;
      local field infiltration with liposomal bupivicane (Exparel). The patients in this study will&#xD;
      include those who have both a clinical and radiographic diagnosis of femoracetabular&#xD;
      impingement (FAI), have failed non operative treatment, and are indicated for hip arthroscopy&#xD;
      with labral repair and femoroplasty/acetabuloplasty. The study includes the surgical&#xD;
      procedure and the first post-operative follow up visit. The total study duration is&#xD;
      approximately 1.5 weeks for each patient. The study will be carried out until the patients&#xD;
      first post-operative visit which typically occurs 7-10 days after the procedure. We are to&#xD;
      include approximately 40 patients in total for this study over a period of 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2019</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>post op days 1-4 (Average VAS score of first 4 days of post op)</time_frame>
    <description>pain scale Questionnaire 0 equals no pain at all and 10 equals the worst. The out come measure time frame is reported as the average VAS score of the first 4 day post op.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic Utilization</measure>
    <time_frame>total pill taken over the course of days 1-4 post op.</time_frame>
    <description>Record of number of narcotic pain pills utilized by patients . This was reported as a total from post op day 1 to 4. The number listed is an average from each patient, from the total pills taken at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of at Home Falls.</measure>
    <time_frame>Post op days 1-7</time_frame>
    <description>number of falls occurring at home after discharge. This is the total number of falls of all patients in each group, over the first 7 days post op. This is not reported as a mean.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Femoro Acetabular Impingement</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fascia iliaca blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivicaine</intervention_name>
    <description>local field infiltration</description>
    <arm_group_label>Liposomal Bupivicaine</arm_group_label>
    <other_name>exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fascia iliaca blockade</intervention_name>
    <description>fascia iliaca compartment blockade</description>
    <arm_group_label>fascia iliaca blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients (&gt;18 years old)&#xD;
&#xD;
          -  diagnosed FAI that are indicated for hip arthroscopic labral repair and&#xD;
             femoroplasty/acetabuloplasty.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients undergoing revision procedures, bilateral procedures,&#xD;
&#xD;
          -  advanced osteoarthritis (&lt;2mm joint space on plain radiographs)&#xD;
&#xD;
          -  frank dysplasia (anterior and/or lateral center edge angles &lt;20 degrees and/or Tonnis&#xD;
             angle &gt;15 degrees)&#xD;
&#xD;
          -  diagnoses other than FAI (Legg Calve Perthes, femoral head avascular necrosis, septic&#xD;
             arthritis, or post traumatic deformity).&#xD;
&#xD;
          -  allergy to liposomal bupivicaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Banffy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerlan Jobe</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J Arthroplasty. 2018 Jan;33(1):90-96. doi: 10.1016/j.arth.2017.07.024. Epub 2017 Jul 25. Erratum in: J Arthroplasty. 2019 Feb;34(2):399-400.</citation>
    <PMID>28802777</PMID>
  </reference>
  <reference>
    <citation>Krych AJ, Baran S, Kuzma SA, Smith HM, Johnson RL, Levy BA. Utility of multimodal analgesia with fascia iliaca blockade for acute pain management following hip arthroscopy. Knee Surg Sports Traumatol Arthrosc. 2014 Apr;22(4):843-7. doi: 10.1007/s00167-013-2665-y. Epub 2013 Sep 24.</citation>
    <PMID>24061718</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <results_first_submitted>March 9, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Banffy, MD</investigator_full_name>
    <investigator_title>Director, Orthopaedic Sports Medicine Fellowship</investigator_title>
  </responsible_party>
  <keyword>hip arthroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Femoracetabular Impingement</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04114058/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivicaine</title>
          <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
        </group>
        <group group_id="P2">
          <title>Fascia Iliaca Blockade</title>
          <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivicaine</title>
          <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
        </group>
        <group group_id="B2">
          <title>Fascia Iliaca Blockade</title>
          <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>BMI utilized for each hip scope .It is a demographic characteristic not a result of the research medication that was being tested . As such, this as not analyzed and standard deviation is not necessary.</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" lower_limit="14" upper_limit="40"/>
                    <measurement group_id="B2" value="25.7" lower_limit="14" upper_limit="40"/>
                    <measurement group_id="B3" value="26.05" lower_limit="14" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Traction time</title>
          <description>Traction time s utilized for each hip scope .It is a demographic characteristic not a result of the research medication that was being tested . As such, this as not analyzed and standard deviation is not necessary.</description>
          <units>MINUTES</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" lower_limit="0" upper_limit="120"/>
                    <measurement group_id="B2" value="36.8" lower_limit="0" upper_limit="120"/>
                    <measurement group_id="B3" value="36.4" lower_limit="0" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pre-op Visual analogue scale score</title>
          <description>Visual analogue scales (VAS) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid (statistically measurable and reproducible) classification of symptom severity and disease control. 0 equals no pain and 10 represents the worst pain.</description>
          <units>CM</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="B2" value="2.2" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="B3" value="2.7" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale</title>
        <description>pain scale Questionnaire 0 equals no pain at all and 10 equals the worst. The out come measure time frame is reported as the average VAS score of the first 4 day post op.</description>
        <time_frame>post op days 1-4 (Average VAS score of first 4 days of post op)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivicaine</title>
            <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
          </group>
          <group group_id="O2">
            <title>Fascia Iliaca Blockade</title>
            <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale</title>
          <description>pain scale Questionnaire 0 equals no pain at all and 10 equals the worst. The out come measure time frame is reported as the average VAS score of the first 4 day post op.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.5" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.8" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Narcotic Utilization</title>
        <description>Record of number of narcotic pain pills utilized by patients . This was reported as a total from post op day 1 to 4. The number listed is an average from each patient, from the total pills taken at home.</description>
        <time_frame>total pill taken over the course of days 1-4 post op.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivicaine</title>
            <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
          </group>
          <group group_id="O2">
            <title>Fascia Iliaca Blockade</title>
            <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
          </group>
        </group_list>
        <measure>
          <title>Narcotic Utilization</title>
          <description>Record of number of narcotic pain pills utilized by patients . This was reported as a total from post op day 1 to 4. The number listed is an average from each patient, from the total pills taken at home.</description>
          <units>number of pills</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="7.8" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of at Home Falls.</title>
        <description>number of falls occurring at home after discharge. This is the total number of falls of all patients in each group, over the first 7 days post op. This is not reported as a mean.</description>
        <time_frame>Post op days 1-7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivicaine</title>
            <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
          </group>
          <group group_id="O2">
            <title>Fascia Iliaca Blockade</title>
            <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of at Home Falls.</title>
          <description>number of falls occurring at home after discharge. This is the total number of falls of all patients in each group, over the first 7 days post op. This is not reported as a mean.</description>
          <units>total number of falls</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events occurred through post op days 1-7 for each patient.</time_frame>
      <desc>An adverse event is defined as a fall post op.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivicaine</title>
          <description>Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control&#xD;
liposomal bupivicaine: local field infiltration</description>
        </group>
        <group group_id="E2">
          <title>Fascia Iliaca Blockade</title>
          <description>Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control&#xD;
Fascia iliaca blockade: fascia iliaca compartment blockade</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not meet target enrollment due to safety concerns.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Banffy</name_or_title>
      <organization>Cedar Sinai -Kerlan Jobe</organization>
      <phone>(310) 665-7200</phone>
      <email>Michael.Banffy@cskerlanjobe.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

